Monte Rosa Therapeutics, Inc. GLUE
11.77
0.05
0.43%
as of 25 Sep
- Market cap
- $999.9M
- P/E
- 0.0×
Follow GLUE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 23.16 |
+8 more quarters Free account |
P/S ratio |
85.49 | 38.25 | 10.53 | 3.36 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 4.21 | |
P/Operating CF |
(55.67) | (43.97) | (30.28) | 6.08 | |
P/B ratio |
5.04 | 3.15 | 5.59 | 2.48 | |
Price to Tangible BV |
5.04 | 3.15 | 5.59 | 2.48 | |
EV/Sales |
63.87 | 22.74 | 7.48 | 1.21 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 13.02 | |
EV/Operating CF |
(76.23) | (66.57) | (40.59) | 1.47 | |
EV/FCF |
(57.19) | (49.70) | (33.66) | 1.51 | |
Quick Ratio |
10.49 | 9.44 | 6.05 | 6.45 | |
Current Ratio |
10.58 | 9.54 | 6.12 | 6.54 | |
Net Debt/EBITDA |
13.15 | 13.88 | 7.92 | 12.67 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.05 | 0.08 | 0.28 | 0.47 | |
Operating CF/Net income |
1.02 | 0.84 | 0.93 | (3.71) | |
Capex/Depreciation |
(2.47) | (0.92) | (0.37) | (0.31) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
534.83% | 1,046.77% | 1,509.49% | 287.27% | |
Selling, General and Administrative Expense of Revenue |
113.00% | 241.69% | 378.17% | 71.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
66.57% | 141.31% | 154.94% | 34.18% | |
Graham Net Nets |
0.17 | 0.28 | 0.14 | 0.31 | |
Graham Number |
0.00 | 0.00 | 0.00 | 4.63 | |
Earnings Yield |
(7.27%) | (9.00%) | (2.93%) | 4.32% | |
Free Cash Flow Yield |
(1.31%) | (1.20%) | (2.11%) | 23.75% | |
Revenue per Share |
0.09 | 0.04 | 0.03 | 0.16 | |
Operating CF per Share |
(0.43) | (0.37) | (0.52) | 1.22 | |
Capex per Share |
(0.05) | (0.02) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.48) | (0.39) | (0.53) | 1.21 | |
Cash per Share |
6.12 | 6.67 | 4.54 | 4.75 | |
Shareholders Equity per Share |
4.80 | 5.23 | 2.81 | 2.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.80 | 5.23 | 2.81 | 2.98 | |
Free Cash Flow |
(48.84) | (39.24) | (43.78) | 99.78 | |
Working Capital |
571.75 | 606.51 | 328.97 | 340.37 | |
Capital Expenditures |
(4.72) | (1.87) | (0.77) | (0.65) | |
Net Current Asset Value |
427.53 | 463.04 | 177.58 | 187.81 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 25.77 | |
Capex to Sales |
0.53 | 0.44 | 0.28 | 0.05 | |
Net Profit Margin |
(483.91%) | (1,057.08%) | (1,658.94%) | (212.10%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 71.74 | |
| Other line items | |||||
Average Receivables |
3.65 | 3.01 | 5.89 | 2.78 | |
Average Payables |
6.37 | 7.19 | 10.38 | 9.24 | |
Average Assets |
525.37 | 564.81 | 443.70 | 387.46 | |
Average Common Equity |
377.68 | 398.54 | 228.00 | 225.65 |
Columns are period end dates